AxoGen, Inc.

AxoGen develops technologies for peripheral nerve regeneration and repair worldwide. Its products include Avance Nerve Graft, AxoGuard Nerve Connector, AxoGuard Nerve Protector, and Axoguard HA+ Nerve Protector. These products are used to bridge severed nerves, protect damaged nerves, and prevent soft tissue attachments. The company also offers Axoguard Nerve Cap, which protects nerve ends and separates them from the surrounding environment. Additionally, AxoGen provides AxoTouch two-point discriminator for measuring skin innervation density. Products are supplied to hospitals, surgery centers, military hospitals, and various surgeons.

Overview

Sector

Medical Devices

Target Price

0.0 USD

Current Price

12.7 USD

Potential

-100%

Strengths

No significant strengths identified based on the analyzed metrics.

Weaknesses

With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
Analysts expect revenues to decline in the coming year.
The company has high debt. Net Debt to EBITDA Ratio (9.45) is higher than the sector mean.
EV/EBIT (100.00) is significantly higher than the sector mean.
The Price to Free Cash Flow ratio (52537.07) is significantly higher than the sector mean.
EBITDA Margin (2.32%) appears relatively low.

Key Financial Data

Indicator	Value
PER	100.0
EV/EBITDA	138.0
Price/Free Cash Flow'	50851.4
ROIC	2.6%
Net Debt/EBITDA	9.5